Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells

Oncogene

Volumn 29, Issue 3, 2010, Pages 356-367

  Jang, G Y ^a   Jeon, J H ^a   Cho, S Y ^a   Shin, D M ^a   Kim, C W ^a   Jeong, E M ^a   Bae, H C ^b   Kim, T W ^b   Lee, S H ^a   Choi, Y ^a   Lee, D S ^a   Park, S C ^a   Kim, I G ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Apoptosis; Caspase 3; Hypoxia inducible factor 1; NF B; Transglutaminase 2

Indexed keywords

CASPASE 3; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENICITY; CATALYSIS; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR CELL;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; PROTEIN MULTIMERIZATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSGLUTAMINASES; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

MUS;

EID: 75149182667     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.342     Document Type: Article

References (45)

1. Aggarwal BB. (2004). Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208.
2. Antonyak MA, Miller AM, Jansen JM, Boehm JE, Balkman CE, Wakshlag JJ et al. (2004). Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 279: 41461-41467.
3. Antonyak MA, Jansen JM, Miller AM, Ly TK, Endo M, Cerione RA. (2006). Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci USA 103: 18609-18614.
4. Baldwin AS. (2001). Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J Clin Invest 107: 241-246.
5. Baylin SB. (1997). Tying it all together: epigenetics, genetic, cell cycle, and cancer. Science 277: 1948-1949.
6. Brown JM, Wilson WR. (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
7. Brunelle JK, Chandel NS. (2002). Oxygen deprivation induced cell death: an update. Apoptosis 7: 475-482.
8. Bubici C, Papa S, Dean K, Franzoso G. (2006). Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25: 6731-6748.
9. Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P et al. (2005). Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 12: 469-475.
10. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ et al. (1997). Targeting gene expression to hypoxic tumor cells. Nat Med 3: 515-520.
11. De Laurenzi V, Melino G. (2001). Gene disruption of tissue transglutaminase. Mol Cell Biol 21: 148-155.
12. Dirmeier R, O'Brien K, Engle M, Dodd A, Spears E, Poyton RO. (2004). Measurement of oxidative stress in cells exposed to hypoxia and other changes in oxygen concentration. Methods Enzymol 381: 589-603.
13. Fesus L, Piacentini M. (2002). Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27: 534-539.
14. Filiano AJ, Bailey CDC, Tucholski J, Gundemir S, Johnson GVW. (2008). Transglutaminase 2 protects against ischemic insult, interacts with HIF1b, and attenuates HIF1 signaling. FASEB J 22: 2662-2675.
15. Giaccia A, Siim BG, Johnson RS. (2003). HIF-1 as a target for drug development. Nat Rev Drug Discov 2: 803-811.
16. Hasegawa G, Suwa M, Ichikawa Y, Ohtsuka T, Kumagai S, Kikuchi M et al. (2003). A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 373: 793-803.
17. Herman JF, Mangala LS, Mehta K. (2006). Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25: 3049-3058.
18. Hui AS, Bauer AL, Striet JB, Schnell PO, Czyzyk-Krzeska MF. (2006). Calcium signaling stimulates translation of HIF-alpha during hypoxia. FASEB J 20: 466-475.
19. Jeon JH, Kim CW, Shin DM, Kim K, Cho SY, Kwon JC et al. (2003a). Differential incorporation of biotinylated polyamines by transglutaminase 2. FEBS Lett 534: 180-184.
20. Jeon JH, Choi KH, Cho SY, Kim CW, Shin DM, Kwon JC et al. (2003b). Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J 22: 5273-5282.
21. Jeon JH, Lee HJ, Jang GY, Kim CW, Shin DM, Cho SY et al. (2004). Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine. Exp Mol Med 36: 576-581.
22. Kaidi A, Qualtrough D, Williams AC, Paraskeva C. (2006). Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66: 6683-6691.
23. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK. (2007). Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLos ONE 2: e1364.
24. Lee KN, Birckbichler PJ, Patterson Jr MK. (1989). GTP hydrolysis by guinea pig liver transglutaminase. Biochem Biophys Res Commun 162: 1370-1375.
25. AAC method. Methods 25: 402-408.
26. Lorand L, Graham RM. (2003). Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4: 140-156.
27. Maxwell PH. (2005). The HIF pathway in cancer. Semin Cell Dev Biol 16: 523-530.
28. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. (2004). Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10: 8068-8076.
29. Mishra S, Murphy LJ. (2004). Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 279: 23863-23868.
30. Park SS, Kim JM, Kim DS, Kim IH, Kim SY. (2006). Transglutaminase 2 mediates polymer formation of ItcBa through C-terminal glutamine cluster. J Biol Chem 281: 34965-34972.
31. Perkins ND. (2007). Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62.
32. Piret JP, Mottet D, Raes M, Michiels C. (2002). Is HIF-1alpha a pro-or an anti-apoptotic protein? Biochem Pharmacol 64: 889-892.
33. Pouyssegur J, Dayan F, Mazure NM. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
34. Reed JC. (2006). Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 3: 388-398.
35. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
36. Shin DM, Jeon JH, Kim CW, Cho SY, Kwon JC, Lee HJ et al. (2004). Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation: implications of transglutami-nase 2 in age-related cataractogenesis. J Biol Chem 279: 15032-15039.
37. Shin DM, Jeon JH, Kim CW, Cho SY, Lee HJ, Jang GY et al. (2008). TGFb mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. FASEB J 22: 2498-2507.
38. Sohn J, Kim TI, Yoon YH, Kim JY, Kim SY. (2003). Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest 111: 121-128.
39. Verma A, Mehta K. (2007). Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 10: 144-151. (Pubitemid 47446401)
40. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. (2000). Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19: 6297-6305.
41. Yamaguchi H, Wang HG. (2006). Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol 26: 569-579.
42. Yuan L, Choi K, Khosla C, Zheng X, Higashikubo R, Chicoine MR et al. (2005). Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther 4: 1293-1302.
43. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. (2000). Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88: 2606-2618.
44. Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D. (2003a). Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 42: 194-208.
45. Zhang Z, Vezza R, Plappert T, McNamara P, Lawson JA, Austin S et al. (2003b). COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res 92: 1153-1161.